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Here, we study immune responses in four DNA/MVA-vaccinated macaques following an SHIV-89.6P challenge and a subsequent CD8 cell
depletion. Both post-challenge and post-depletion peaks of viremia contracted with the expansion, or re-emergence, of CD8 T cells. Post-
depletion, CD8 cells expanded in the presence of higher levels of neutralizing Ab and CD4 help than post-challenge and had superior maturational
characteristics as measured by expression of the anti-apoptotic protein Bcl-2, the IL-7 receptor CD127 and co-production of IFN-g and IL-2. Pre-
challenge and pre-depletion titers of neutralizing Ab correlated inversely with peaks of viremia and directly with peaks for anti-viral CD4 cells.
Thus, our results reveal CD8 cells playing a central role, and neutralizing Ab, a supporting role in SHIV-89.6P control. They also suggest a
dynamic relationship between neutralizing Ab, antigen load and anti-viral CD4 cells in the maturation of high-quality anti-viral CD8 T cells.
D 2005 Elsevier Inc. All rights reserved.
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No single immune correlate for the control of immunode-
ficiency virus infections has been defined. Transient in vivo
depletions of CD8 T cells in macaques have revealed a critical
role for anti-viral CD8 T cells in the control of both acute and
chronic SIV (Jin et al., 1999; Metzner et al., 2000; Schmitz et
al., 2005, 1999a) and SHIV (Rasmussen et al., 2002)
infections. The passive transfer of antibody prior to pathogenic
challenges has demonstrated the ability of neutralizing Ab to0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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E-mail address: rama@rmy.emory.edu (R.R. Amara).provide protection (Mascola et al., 1999, 2000, 2003;
Nishimura et al., 2002, 2003; Parren et al., 2001; Shibata et
al., 1999). Adaptive transfer of autologous pre-infection CD4 T
cells improves viral control in macaques chronically infected
with SIV (Villinger et al., 2002). Thus, there are precedents for
protective roles for anti-viral CD8 T cells, neutralizing Ab and
anti-viral CD4 T cells.
In 2001, we demonstrated that an SHIV-89.6 vaccine
consisting of priming with DNA and boosting with modified
vaccinia Ankara (MVA) could effectively control a pathogenic
challenge with a chimera of simian and human immunode-
ficiency viruses (SHIV-89.6P) in rhesus macaques (Amara et
al., 2001; Sadagopal et al., 2005; Tang et al., 2002). This
DNA/MVA vaccine elicits high frequencies of anti-viral CD8
and CD4 T cells and has been hypothesized to control5) 246 – 255
www.e
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The group of animals used for CD8 depletions was a parallel
group of animals in which we had administered GM-CSF
DNA with the vaccine DNA to test the potential for GM-CSF
DNA to serve as a genetic adjuvant. The GM-CSF group was
chosen instead of a non-adjuvanted group because it had
shown a trend towards better viral control and therefore was a
good group to test for depletion-induced viral re-emergence
(work in progress). We also desired to maintain our non-
adjuvanted groups without perturbation to follow long-term
viral control.
Because chronic infections can affect the function of
responding CD8 T cells by the presence of persisting antigen
or by compromising CD4 T cell help (Appay et al., 2000;
Champagne et al., 2001; Wherry et al., 2003), we undertook
temporal characterization of anti-viral CD8 cells for the 1st
year following the initial challenge, as well as for a year
following a subsequent CD8 T cell depletion. By characterizing
CD8 responses following both challenge and depletion, we
were able to examine temporal CD8 responses in the same
animal in the presence of different levels of viremia,
neutralizing Ab and CD4 T cell help. These characterizations
focused on testing for functional characteristics that are critical
for the long-term control of chronic viral infections (Kalams
and Walker, 1998). Memory CD8 T cells with good functional
characteristics possess high proliferative capacity to recall
antigens (Kaech et al., 2002) and express high levels of the
anti-apoptotic protein Bcl-2 (Grayson et al., 2000) and the
interleukin-7 receptor a chain CD127 (Kaech et al., 2003).Fig. 1. Temporal Gag-CM9 tetramer-specific CD8 T cells and viral RNA levels post
T cells enumerated using the Gag-CM9 tetramer. The frequency of tetramer-positive
RNA levels post-SHIV challenge and CD8 cell depletion. Arrowheads at the top
antibody administration.Following antigen stimulation, they produce interleukin-2 (IL-
2) and TNF-a in addition to IFN-g (Slifka and Whitton, 2000).
In contrast, functional exhaustion is associated with a
progressive loss of proliferative capacity and cytokine produc-
tion, with the loss of IL-2 production being the first indicator of
T cell exhaustion (Wherry et al., 2003). IL-2 is important for T
cell proliferation and has the potential to increase T cell
survival (Akbar et al., 1996) and sustain the ability of CD8
cells to produce IFN-g (Su et al., 1998). Our results highlight
the central role of CD8 T cells in long-term vaccine-mediated
control of SHIV-89.6P and suggest a dynamic relationship
between the titer of neutralizing Ab, the blunting of antigen
loads, the protection of CD4 T cells and the maturation of high-
quality memory anti-viral CD8 T cells.
Results
Vaccine trial used for CD8 depletion study: post-vaccine and
post-challenge T cells and viremia
Four macaques from a DNA/MVA vaccine group that
had been challenged with SHIV-89.6P were used to study
post-challenge and post-depletion immune responses in
viral control. These macaques had been vaccinated with
0.25 mg of DNA/89.6 plus 0.25 mg of GM-CSF DNA at
weeks 0 and 8, boosted with MVA/89.6 on week 24 and
challenged with the pathogenic SHIV-89.6P at 7 months
after the rMVA boost. Two of the four test macaques were
positive for the Mamu A*01 allele that recognizes thevaccination, challenge and CD8 depletion. (A) Frequency of Gag-specific CD8
cells is represented as a percent of total CD8 T cells. (B) Temporal plasma viral
of panel (A) indicate the time points of vaccination, challenge and anti-CD8
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2000).
The frequencies of anti-viral CD8 T cells in blood rapidly
expanded and contracted following MVA boost and SHIV-
89.6P challenge (Fig. 1A). Following the two DNA
inoculations, the frequencies of Gag-CM9 tetramer-positive
cells in the two A*01 positive macaques were below our
detection limit. However, at 1 week after the rMVA boost,
these cells were readily detected and had a frequency of 0.5
and 2.0% of total CD8 T cells. As these cells differentiated
into memory, they underwent a 10- to 20-fold contraction
and were present at very low levels at the time of SHIV-
89.6P challenge. Following challenge, all four macaques
experienced high levels of viremia, which peaked by 2
weeks at titers from 2106 to 6108 copies per milliliter
of plasma (Fig. 1B). The vaccine-elicited Gag-CM9 tetra-
mer-staining cells expanded rapidly, reaching frequencies of
10% of total CD8 T cells by 3 weeks post-challenge (Fig.
1A). As anti-viral CD8 T cells appeared, virus was
controlled, reaching the background for detection by 16 to
32 weeks post-challenge (Fig. 1B). Concomitant with viral
control, the number of tetramer-staining cells contracted by
about 10-fold (Fig. 1A). Control was maintained over time,
with each of the macaques stably controlling plasma viral
RNA to below our limit for detection (300 copies of viral
RNA per milliliter of plasma) (Fig. 1B). IFN-g ELISPOT
analyses followed the same trends as the tetramer analyses
(data not shown).Fig. 2. Anti-viral CD8 T cells play a critical role for the control of re-emergent virus.
indicate the time points of anti-CD8 antibody administration and shaded areas, the l
and the open symbols represent A*01-negative macaques. (B) Temporal post-deple
ICS and plasma viral load. For ICS assays, PBMC were stimulated with four G
administration and shaded areas, the length of CD8 depletion. The filled symbols r
RNA.Transient CD8 depletion, re-emergence of viremia and rapid
expansion of anti-viral CD8 cells
Transient CD8 depletion studies at 2 years post-challenge,
a time when virus had been controlled to below our level of
detection for more than 1 and 1/2 years resulted in a rapid
yet transient outgrowth of virus in all four macaques (Figs.
1 and 2). Administration of the anti-CD8 monoclonal
antibody, cM-T807, on days 0, 3 and 7, depleted almost
all CD8 T cells but relatively few CD4 T cells from the
blood (Fig. 2A). Viral loads began to re-emerge within 3
days of depletion and had peaked at up to 5106 copies
per milliliter of plasma by 2 weeks post the 1st adminis-
tration of the depleting Ab (Figs. 1B and 2). Impressively,
as anti-viral CD8 T cells began to reappear in blood at 14 to
16 days post-depletion, all four animals rapidly regained
control of virus replication. In the two A*01 macaques,
Gag-CM9-specific CD8 cells peaked at frequencies as high
as 10% of total CD8 T cells. ICS analyses revealed a
similar temporal pattern for total Gag-specific CD8 T cells
in all four macaques (Fig. 2B). These results demonstrate
the important role of virus-specific CD8 T cells for the long-
term control of SHIV-89.6P by a DNA/MVA vaccine in
macaques.
The cM-T807 Ab also depletes NK cells (CD8+, CD3
cells) in addition to CD8 T cells, raising the possibility of the
involvement of NK cells in viral control. However, we suggest
that this was unlikely because essentially undetectable levels of(A) Temporal post-depletion analyses for total CD8 and CD4 cells. Arrowheads
ength of CD8 depletion. The filled symbols represent A*01-positive macaques,
tion analyses for total Gag-specific IFN-g-producing CD8 cells determined by
ag peptide pools. Arrowheads indicate the time points of anti-CD8 antibody
epresent Gag-specific CD8 cells, and the open symbols represent plasma viral
Fig. 3. Temporal comparisons of post-challenge and post-depletion viral loads and immune responses. (A) Viral loads, (B) Gag-CM9-tetramer-specific CD8 cells, (C)
IFN-g-producing Gag-specific CD8 T cells scored using ICS. The left hand panels present the geometric mean of data for the test animals. The middle and right hand
columns present data for individual animals post-challenge or post-depletion. For ICS assays, PBMC were stimulated with four Gag peptide pools. For post-
depletion ICS assays, analyses from day 16 were plotted at week 2. Post-challenge data are presented as open symbols and post-depletion data as filled symbols.
Symbols for animals are the same as in Fig. 1.
Fig. 4. Temporal frequency of CD8 cells co-producing IFN-g and IL-2 in response to peptide Gag-CM9 stimulation post-depletion and post-challenge. (A) FACS
plots demonstrating the temporal frequency of cells co-producing IFN-g and IL-2 for REz5. (B) Kinetic patterns for cells co-producing IFN-g and IL-2 post-
challenge and post-depletion for REz5 and RQv4. To determine the co-expression of IFN-g and IL-2, PBMC were stimulated with Gag-CM9 peptide for 6 h, fixed
and stained for CD3, CD8, IFN-g and IL-2. Cells were gated on lymphocytes based on the scatter pattern then on CD3 and CD8 and analyzed for expression of IFN-g
and IL-2. The frequencies in the upper right quadrants are IL-2-producing cells as the percent of total IFN-g-producing cells. The differences in the positioning of gates
for post-challenge and post-depletion samples are due to the use of different flourochrome conjugates and have been determined based on their respective unstimulated
cells.
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of plasma viral RNA were declining.
Similar heights of Gag-specific CD8 T cell responses but
different viral loads post-depletion and post-challenge
The frequency of Gag-specific CD8 responses had similar
heights post-challenge and post-depletion, while peak viral
loads were 100-fold lower post-depletion (Fig. 3). TheFig. 5. Temporal presence of the memory markers Bcl-2 and CD127 on Gag-CM9 te
demonstrating the temporal frequency of cells expressing Bcl-2 and CD127. Cells we
analyzed for expression of tetramer and the respective phenotypic marker. The numb
phenotypic marker as the percent of total tetramer-positive cells. (B) Comparison of
times post-challenge and post-depletion for macaques REz5 and RQv4.geometric mean for the peak titer of viral RNA was 2105
copies per milliliter of plasma post-depletion, compared to
1107 copies per milliliter of plasma post-challenge (Fig. 3A).
Also, post-depletion, all four animals controlled their viral
loads to below detectable levels within 5 weeks, whereas
complete control required up to 32 weeks post-challenge.
Despite the different peaks in viral RNA, in the two A*01
monkeys, tetramer-positive cells had indistinguishable peak
frequencies post-depletion and challenge (Fig. 3B). The ICStramer-staining CD8 T cells post-challenge and post-depletion. (A) FACS plots
re gated on lymphocytes based on the scatter pattern then on CD3 and CD8 and
ers in the upper right quadrants are tetramer-positive cells positive for the tested
the kinetics of expression of Bcl-2 and CD127 by anti-viral CD8 cells at various
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patterns and comparable peak responses for total Gag-specific
IFN-g-producing CD8 T cells post-depletion and challenge
(Fig. 3C).
Different frequencies of IFN-c and IL-2 co-producing CD8
T cells post-depletion and post-challenge
The proportion of the anti-viral CD8 T cells capable of co-
producing IFN-g and IL-2 was higher post-depletion compared
to post-challenge (Fig. 4). At 3 weeks post-depletion, about
35% of the IFN-g-producing CD8 cells co-produced IL-2,
whereas only 10% of the post-challenge cells also produced
IL-2 (Fig. 4). As cells differentiated into memory, the pro-
portion of IFN-g-producing cells that co-produced IL-2
increased. However, the post-challenge cells continued to have
overall lower frequencies IFN-g-producing cells that co-
produced IL-2 than the post-depletion CD8 cells. At 8 weeks,
approximately 50% of the cells from the post-depletion time
point co-produced IL-2, whereas only 30% of the cells from theFig. 6. Temporal comparisons of post-challenge and post-depletion Gag-specific CD
cells determined using four pools of Gag peptides to stimulate PBMC and ICS anal
killing assay. Titers are the reciprocal for 50% killing determined using neutral red. F
for the test animals. The left and middle hand panels present data for individual anim
symbols and post-depletion data as filled symbols. Symbols for animals are the same
challenge titers of neutralizing Ab (open symbols) and post-depletion viral load and
between the frequency of anti-Gag CD4 T cells at 2 weeks post-challenge and the tite
and the titer of pre-depletion neutralizing Ab (closed symbols).post-challenge time point co-produced IL-2. By 34 weeks, the
proportion of IFN-g-producing cells that co-produced IL-2 was
similar for macaque RQv4 but was still higher for macaque
REz5. Similar results were also observed in the two non-A*01
monkeys at the peak time point when the frequencies of
responding IFN-g-producing CD8 cells were sufficiently high
for IL-2 measurements (>0.05% of total CD8 T cells). Based on
the staining intensity for IFN-g at weeks 3 and 8 (Fig. 4A), it
appears that the post-challenge CD8 T cells are making more
IFN-g per cell compared to post-depletion cells. However, we
believe that these differences are due to the use of different
flourochrome conjugates (see figure legend) at these two time
points and are not due to a difference in the amount of cytokine
per cell.
More rapid differentiation into memory post-depletion than
challenge
The presence of a higher frequency of Gag-specific CD8
cells co-producing IFN-g and IL-2 post-depletion than post-4 T cells and 89.6P neutralizing Ab. (A) Gag-specific IFN-g-producing CD4 T
yses. (B) Titers of SHIV-89.6P neutralizing Ab determined using an MT-2 cell
or panels (A) and (B), the right hand panels present the geometric mean of data
als post-challenge or post-depletion. Post-challenge data are presented as open
as in Fig. 1. (C) Negative correlation between post-challenge viral load and pre-
pre-depletion titers of neutralizing Ab (closed symbols). (D) Positive correlation
r of pre-challenge neutralizing Ab (open symbols) and at 2 weeks post-depletion
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different patterns of differentiation into memory. To test for
differentiation into memory, we measured the expression of the
anti-apoptotic protein Bcl-2 and the expression of CD127, the
a-chain of the interleukin-7 receptor, at various times post-
depletion and post-challenge. Bcl-2 indicates survival potential,
while CD127 confers both survival potential and proliferative
capacity (Kaech et al., 2003; Paiardini et al., 2005). For these
analyses, we used samples from weeks 3, 12, 24 and 52 post-
depletion or post-challenge. At peak effector phase (3 weeks),
the vast majority of tetramer-positive cells (about 90%) were
negative for expression of Bcl-2 and CD127. As cells
differentiated into memory, the proportion of tetramer-positive
cells expressing either Bcl-2 or CD127 increased more rapidly
in the post-depletion than in the post-challenge samples. A
much higher proportion of Gag-specific CD8 cells expressed
the anti-apoptotic protein Bcl-2 at 6 months post-depletion than
post-challenge (72% as opposed to 34% for REz5 and 45% as
opposed to 17% for RQv4) (Fig. 5B). Similarly, a higher
proportion also expressed CD127 at 6 months post-depletion
than post-challenge (59% as opposed to 46% for REz5 and
42% as opposed to 21% for RQv4) (Fig. 5B). Differences in
the frequencies of Bcl-2 and CD127-positive cells narrowed
over time but were maintained for at least 1 year.
Comparison of CD4 T cell responses and neutralizing Ab
post-depletion and post-challenge
Peak levels of Gag-specific CD4 cells were about 80-fold
higher post-depletion than post-challenge (Fig. 6A), and the
titers of SHIV-89.6P-specific neutralizing antibodies were
about 50-fold higher post-depletion than post-challenge (Fig.
6B). The differences in CD4 and neutralizing Ab responses
narrowed over time but were still present at 8 weeks post-
challenge, when anamnestic responses had begun to contract.
To test for a possible supporting role of neutralizing Ab in
the blunting of viral RNA and the protection of anti-viral CD4
T cells, pre-challenge and pre-depletion titers of neutralizing
Ab were compared to the peak titers of post-challenge or post-
depletion viremia. Comparisons were also made with the
frequencies of anti-viral CD4 T cells at 2 weeks post-challenge.
These comparisons revealed a strong negative correlation
between the titers of neutralizing Ab and the corresponding
peak titers of plasma viral RNA (P = 0.02, r = 0.90) (Fig.
6C) and a strong positive correlation between the titers of
neutralizing Ab and the corresponding frequencies of anti-viral
CD4 T cells (P = 0.02, r = 0.90) (Fig. 6D).
Discussion
Our results demonstrate that CD8 T cells are important for
the long-term control of SHIV-89.6P infections by a DNA/
MVA vaccine. CD8 depletions resulted in the rapid re-
emergence of virus in vaccinated animals that had controlled
SHIV-89.6P to below 300 copies per milliliter of plasma for
more than 1 and 1/2 years. These results confirm the central
role of CD8 T cells for immunodeficiency virus control andextend previous CD8 depletion studies using SIV (Jin et al.,
1999; Metzner et al., 2000; Schmitz et al., 2005, 1999a) and
SHIV-infected macaques (Rasmussen et al., 2002) to long-term
viral control in DNA/MVA-vaccinated and SHIV-89.6P-chal-
lenged macaques. We also evaluated the kinetics of virus-
specific neutralizing antibody and anti-viral CD4 cells post-
challenge and depletion. These analyses demonstrated that the
presence of good titers of 89.6P-specific neutralizing Ab at the
time of depletion (geometric mean titer of 1:800 for 50%
inhibition of MT-2 cell killing) and strong anamnestic
expansions of neutralizing Ab and CD4 T cell responses
post-depletion were not sufficient to control re-emergent
viremia triggered by CD8 T cell loss.
Interestingly, the CD8 T cells that emerged post-depletion
had better functional characteristics than those that emerged
post-challenge as defined by their ability to co-produce IFN-g
and IL-2 and express Bcl-2 and CD127. The peak height of
IFN-g-producing CD8 cells was the same post-depletion and
post-challenge. However, on average, 35% of the peak post-
depletion IFN-g response co-produced IL-2, as opposed to only
10% of the peak post-challenge IFN-g response. Preservation
of the capacity of anti-viral CD8 T cells to co-produce IL-2 and
IFN-g has been shown to be associated with better control of
both SIV and SHIV infections of macaques (McKay et al.,
2002; Sadagopal et al., 2005) and HIV infections in humans
(Boaz et al., 2002; Harari et al., 2005). Also, following the
control of viremia, effector CD8 cells differentiated more
rapidly into memory post-depletion than post-challenge. This
was shown by higher frequencies of cells expressing the anti-
apoptotic protein Bcl-2 and the IL-7 receptor a chain, CD127,
post-depletion than post-challenge.
A number of factors could have influenced the enhanced
function and more rapid differentiation of CD8 T cells into
memory post-depletion than post-challenge. Important among
these are antigen load and CD4 T cell help. Post-depletion,
peak viremia was lower and of shorter duration than post-
challenge. Antigen load directly drives the levels of anti-viral
T cells and can influence their cytokine expression.
Consistent with this, a recent study demonstrates that
different levels of antigen influence the co-production of
IFN-g and IL-2 by virus-specific CD4 T cells. In this study,
antigen clearance was associated with a single dominant IL-
2-producing CD4 T cell response; the persistence of low
levels of antigen was associated with a response consisting
of IL-2, IL-2 plus IFN-g and IFN-g only producing CD4 T
cells; and the persistence of high levels of antigen was
associated with a single dominant IFN-g response (Harari et
al., 2005). CD4 T cells were present at 5 to 50 times higher
levels post-depletion than post-challenge. CD4 T cells are
critical for the generation of ‘‘functional’’ CD8 T cells.
Recent experiments in mice demonstrate that CD8 T cell
priming in the absence of CD4 help results in the generation
of CD8 T cells that are defective in their ability to expand
following secondary antigen exposure (Bourgeois et al.,
2002; Janssen et al., 2003; Shedlock and Shen, 2003; Sun
and Bevan, 2003). In the absence of CD4 help, anti-viral
CD8 T cells are either deleted or persist in a non-functional
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(Zajac et al., 1998). Therefore, we suggest that lower levels
of antigen coupled with higher levels of CD4 T cell help
contributed to the enhanced CD8 function and memory
differentiation post-depletion than post-challenge.
Our results also suggest that both neutralizing Ab and anti-
viral CD4 T cell help contributed to protection. The titers of
neutralizing Ab that were present either pre-challenge or pre-
depletion correlated inversely with peak viremia (r = 0.9,
P = 0.02) and directly with the magnitude of the anamnestic
CD4 response (r = 0.9, P = 0.02). These correlations suggest
that neutralizing Ab helped blunt viral loads by blocking
infections and helped preserve anti-viral CD4 T cells by
limiting the infection of these cells, which are preferential
targets for immunodeficiency viruses (Douek et al., 2002; Li et
al., 2005; Mattapallil et al., 2005). A role for neutralizing Ab in
preserving CD4 T cell help may be particularly relevant to
SHIV-89.6P infections which are highly cytopathic for CD4
T cells.
The GM-CSF adjuvant did not have an obvious effect on the
temporal patterns of CD8 T cells elicited post-vaccination and
post-challenge (Fig. 1, and group 3 of Amara et al., 2001).
However, it did appear to affect the affinity maturation and the
breadth of the neutralizing Ab response, a phenomenon that is
currently being tested for reproducibility.
In conclusion, our results highlight the central role of CD8 T
cells in long-term vaccine-mediated control of SHIV-89.6P and
suggest a dynamic relationship between the titer of neutralizing
Ab, the blunting of antigen loads, the protection of CD4 T cells
and the maturation of high-quality memory anti-viral CD8 T
cells. Thus, we suggest that the most effective vaccines for
HIV-1 will not only elicit anti-viral CD8 T cells but also will




The construction and production of the DNA and MVA
immunogens have been previously described (Amara et al.,
2001). The SHIV-89.6 DNA (DNA/89.6) used the pGA vector
to express Gag, Pol, Env, Tat, Rev, Vif, Vpr and Vpu from a
single RNA transcript by Rev-dependent subgenomic splicing.
The rMVA (MVA/89.6) expressed SHIV-89.6 Gag, Pol and
Env using a synthetic early/late promoter and insertion sites III
and II, respectively. The 89.6 Env protein in the MVA/89.6 was
truncated for the COOH-terminal 115 amino acids of gp41. The
macaques used for this trial were ones in which a GM-CSF
expressing DNA had been used as a genetic adjuvant for the
DNA immunizations. The macaque GM-CSF gene was
expressed in the pGA expression vector (Hutchinson et al.,
2001). All vaccinated animals received 0.25 mg of DNA
expressing macaque GM-CSF mixed with 0.25 mg of DNA/
89.6 in a single intradermal inoculation at 0 and 8 weeks and
2108 pfu of MVA/SHIV-89.6 delivered both intradermally
and intramuscularly at 24 weeks. At 7 months after the rMVAbooster, animals received an intrarectal challenge with SHIV-
89.6P using a pediatric feeding tube to introduce 20 intrarectal
infectious units (1.21010 copies of SHIV-89.6P viral RNA)
15 to 20 cm into the rectum. The animal designations are the
following: RQv4, REz5, RPa5 and RRe6. RQv4 and REz5 are
Mamu A*01 positive; RPa5 and RRe6 are Mamu A*01
negative. Young adult Indian rhesus macaques from the Yerkes
breeding colony were used for immunizations and cared for
under guidelines established by the Animal Welfare Act and
the NIH ‘‘Guide for the Care and Use of Laboratory Animals’’
using protocols approved by the Emory University Institutional
Animal Care and Use Committee.
CD8 cell depletion
CD8 depletion was conducted at about 2 years post-
challenge. Briefly, the anti-monkey CD8 mouse–human
chimeric monoclonal antibody (clone cM-T807) was adminis-
tered on days 0, 3 and 7 (Schmitz et al., 1999a, 1999b). The
first injection was given at a dose of 10 mg/kg subcutaneously,
and the subsequent two injections were given at a dose of
5 mg/kg, intravenously. This procedure achieves near total
depletion of CD8 T cells from the blood without significant
changes in the CD4 T cell population.
Viral RNA measurements
SHIV copy number was determined using a quantitative real
time PCR as previously described (Amara et al., 2001;
Hofmann-Lehmann et al., 2000). All specimens were extracted
and amplified in duplicate, with the mean result reported. The
background for detection of SHIV-89.6P viral RNA was 300
copies per milliliter of plasma, and animals with levels of virus
below 300 were scored at 300.
T cell responses
CD8 positive T cells in whole blood were measured by four-
color flow cytometry as described previously (Schmitz et al.,
1999a) using antibodies specific to CD3 (FN18, Biosource
international), CD8 (DK25; Dako, Carpinteria, CA, USA),
CD20 (L27, BD, San Jose, CA) and CD4 (SK3, BD, San Jose,
CA). DK25 can bind to CD8 in the presence of cM-T807.
Tetramer analyses for Gag-CM9-specific CD8 cells and assays
for intracellular cytokine staining (ICS) have been previously
described (Amara et al., 2001). The ICS analyses used either
pools of overlapping peptides for SIV Gag (22 mers over-
lapping by 10, 4 pools, 10–13 peptides per pool) or the Gag-
CM9 peptide (CTPYDINQM) for stimulations. For phenotypic
analyses, PBMC were stained with anti-CD3, anti-CD8, the
Gag-CM9 tetramer, anti-CD127 (50503, R&D Systems Inc.)
and anti-Bcl-2 (6C8, BD Pharmingen, San Jose, CA).
Neutralizing antibody assays
The titers of neutralizing antibody for SHIV-89.6P were
determined using MT-2 cell killing and neutral red staining
R.R. Amara et al. / Virology 343 (2005) 246–255254(Montefiori et al., 1988). Neutralization titers are the reciprocal
of the serum dilution that protected 50% of cells from the
killing effects of the indicated viruses grown in human PBMC.
This cut-off corresponds to an approximate 90% reduction in
virus yield (Bures et al., 2000).
Statistical analysis
Spearman’s rank correlation coefficient was used to test
whether neutralizing antibody correlated with viral load and
Gag-specific CD4 cells.
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